Mekinist Approval History
- FDA approved: Yes (First approved May 29th, 2013)
- Brand name: Mekinist
- Generic name: trametinib
- Company: GlaxoSmithKline
- Treatment for: Melanoma, Metastatic
Mekinist (trametinib) is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.
FDA Approval History for Mekinist
|May 29, 2013||FDA Approves Mekinist (trametinib) for Advanced Melanoma|
|May 1, 2013||Regulatory Update: Trametinib US PDUFA Date Extended to 3 September 2013|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.